CA1263119A - Production of 2-(2- pyridylmethylsulfinyl)benzimidazole compounds - Google Patents

Production of 2-(2- pyridylmethylsulfinyl)benzimidazole compounds

Info

Publication number
CA1263119A
CA1263119A CA000573673A CA573673A CA1263119A CA 1263119 A CA1263119 A CA 1263119A CA 000573673 A CA000573673 A CA 000573673A CA 573673 A CA573673 A CA 573673A CA 1263119 A CA1263119 A CA 1263119A
Authority
CA
Canada
Prior art keywords
vanadium
alkyl
compound
alkoxy
fluorinated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000573673A
Other languages
French (fr)
Inventor
Masayasu Kato
Yoshio Toyoshima
Norio Iwano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16330618&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1263119(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of CA1263119A publication Critical patent/CA1263119A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Abstract of the disclosure 2-(2-pyridylmethylsulfinyl)benzimidazole compounds are produced by subjecting 2-(2-pyridylmethylthio)benz-imidazole compounds to oxidation with hydrogen peroxide in the presence of vanadium compounds in good yield and with low production of by-products.

Description

3LZ6~

1 Produc-tion of 2-(2-pyridylmethylsulElnyl)benzimidazole .
Compounds -This invention relates to ~he production of 2-(2-pyridylmethylsulEinyl)benzimidazole compounds (refer to, for example, U.S. Patent No.4255~31, European Patent Laid-Open No.45200, No.74341, No.80602, Mo.5129, No.174726, No.175464, sritish Patent Laid-Open No.2134523A), which are useful as antiulcer agents.

~s a method for production of 2-(2-pyridyl-methylsulfinyl)benzimidazole compounds, an oxida-tion o~ the corresponding 2-(2-pyridylmethyl-thio)benz-imidazole compounds with m-chloroperbenzoic acid is mentioned (r~ r to, for example, U.S. Patent No.4255431, European Patent Laid-Open No~0602).
Generally known methods for production of sulfoxides from sulfides include oxidation with peracid, hydrogen peroxide, iodosobenzene, N-halosuccinimide, tertiary butyl hypochloride, sodium metaperiodate, selenium dioxide, bromine, chlorine, or ozone [Refer -to: Saul Patai, The chemistry of ethers, crown ethers, hydroxyl groups and their sulphur analogues, Supplement E, Part 1, p.539-608, John Wllley & Sons, An In-terseience Publication (1980), Miehel Madeselaire, Tetrahedron ~eport Number 210, "Syn-thesis of Sulfoxides by Oxidation of Thioethers", Tetra-hedron, 42, 5459-5~95 (1986)].
~ lowever, the speeifications or referenees do not inelude eoncrete examples of prac-tieal production of 2-(2-pyridylmethylsulfinyl)benzimida-zole eompounds by o~idation with hydrogen peroxide as theoxidizin~ a~ent.

Oxidat:lon of 2-(2-pyridylmethylthio)benzimidazole eompounds with m-ehloroperbenzole aeid gives 2-(2-pyridyl-me~h-ylsulfinyl)benzimldazole eompounds only in low yields, producing much side products such as 2-(2~pyridylmethyl-1 sul~onyl)benzimidazole N-oxide. Such side products are very difficult to remove from 2-(2-pyridylmethylsul-finyl)benzimidazole compounds with usual methods of puri-fication, such as recrystallization. Expensiveness of m chloroperbenzoic acid is an additional problem.
There are some problems in oxidation of 2-(2-pyridyl-methylthio)benzimidazole compounds with one of the oxi-, dizing agents described above other than hydrogen per-oxide; the reaction will not proceed in many cases, and the yield is very low (less than about 75~) because of degradation or production of a great ammount of hy-products.

As the resul-ts of the inventors' researches to find a method for production of 2-(2-pyridylmethylsulfinyl)benz-imidazole compounds from 2-(2-pyridylmethyl-thio)benzimida-zole compounds in good yield and with low production of by-products such as 2-(2-pyridylmethylsulfonyl)benz-imidazole N-oxides, -the inventors have found -that oxidation wi-th hydrogen peroxide in the presence of vanadium com-pounds, for example,vanadium oxides or vanadium salts. asthe catalyst accomplishes the purpose, and have comPleted the in~ention after further researches.
This invention relates to a method for producing ~ compound having the formula (II):
~ R~

wherein the ring A may be substituted; R1 is a hydrogen atom or an N-protective group; R2, R3 an~ R~ are independently hydrogen atom, an alkyl group which may be Eluorinated or an alkoxy group which may ~e fluorinated, which comprise~ subjecting a compound having the Eormula (I):

i3.

l~vrN~--S_Cll~

wher~in ~, R1, R2, R3 and R4 are the same as described above, to oxidation with hydrogen peroxide in -the presence of vanadium compounds.
In compounds (I) and (II~, -the substituents in the ring A include alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio and alkylsulfi-nyl etc. The alkyl groups are desirably those having to 7 carbon atoms, including methyl, ethyl, propyl, iso-propyl, butyl, isobutyl, pentyl, hexyl and heptyl e-tc.
The halogen atoms include fluorine, chlorine and bromine atoms, among which the fluorine atom is the most desirable.
The carboalkoxy groups are desirably those in which the alkoxy group has l to 4 carbon atoms, including carbo-methoxy (CH300C-) and carboethoxy (C2H500C-) etc. The carboalkoxyalkyl groups are desirably those in which the alkoxy and alkyl groups have 1 to 4 carbon atoms each, including carbomethoxymethyl (CH300CCH2-), carbomethoxy-ethyl (CH300CC2H4-), carboethoxyllle-thyl (C2ll500CCH2-) and carboethoxyethyl (C2H500CC2H4 ~ etc. The carbamoyla~kyl groups are desirably thosè in which the alkyl group has 1 to 4 carbon atoms, including carbamoylmethyl (~l2NCOCH2-) and carbamoylethyl (H2NCOC2H~-) e-tc. The alkoxy groups are desirably those haviny 1 to 5 carbon atoms, including methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy anc1 pentoxy etc. The hydroxyalkyl groups are desirably those.in which ~le alk~l ~roup has 1 to 7 carbon atoms, inclu-diny hydroxymethyl and 1-hydroxy-propyl-2,1-hydroxy-ethyl-2,1-hydroxy-2-metl1yl-propyl-2 e-tc. The acyl 1 groups are desirably those having 1 to ~ carbon atoms, including formyl, acetyl, propionyl, butylyl an~ isobuty-lyl etc. T~le acyloxy groups are desirably those in which the acyl group has 1 to 4 carbon atoms, including ~or-myloxy, acetyloxy, propionyloxy, butylyloxy, and iso-butylyloxy etc. The aryl groups include phenyl, tolyl and naphthyl etc. The aryloxy groups include phenyloxy, tolyloxy and naphthyloxy etc. The alkylthio groups are desirably those in which the aLkyl group has 1 to 4 carbon atoms, including methylthio, ethylt}lio and propylthio etc The alkylsulfinyl groups are desirably those having l to 6 carbon atoms, including methylsulfinyl, ethylsulfi-nyl and propylsulfinyl e-tc.
The ring A is not substituted or is substituted at the 4- or 5-position particularly desirably with alkyl, halogen, trifluoromethyl or alkoxy among the substituents described above.
The N-protective groups represen-ted by R1 include alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonyl-me-thyl and alkylsulfonyl etc. The alkyl groups are desirably those having 1 to 5 carbon atoms, including methyl, ethyl, propyl, isopropyl, butyl, isobutyl and pentyl etc. The acyl groups include the same ~roups as those described ~or the substituents o~ the ring ~. The carboalko~y groups include the same groups as those described for the substituents of the ring A. The alkylcarbamoyl groups are represented by the Eormula:
}~

alkyl wherein the alkyl group has desirably 1 to ~ carbon atoms, includlng me-thylcarbamoyl, ethylcarbamoyl, propylcarba-moyl and isopropylcarbamoyl e~c. The dialykylcarbamoyl 5 groups are r~presented by the formula:
allcyl\

alkyi/

.. . .. .

~L~

1 wherein the ~lkyl groups have desirably 1 to 4 carbon ~toms each, includin~ dimethylcarbamoyl, dietllylcarbamoyl and N-methyl-N-ethylcarbamoyl e-tc. The alkylcarbonyl-methyl groups are represented by the Eormula: alkyl-CO-C1~2- wherein the alkyl group has desirably 1 to 4 carbon atoms, including acetylmethyl and propionylmethl etc.The alkoxycarbonylmethyl groups are represen-ted by the formula: alkyl-OCO-CH2- wherein the alkyl group h~s desir-ably 1 to 4 carbon atoms, including methoxycarbonylmethyl, ethoxycarbonylmethyl and propoxycarbonylmethyl etc. The alkylsulfonyl groups are represented by -the formula:
alkyl-SO2- wherein the alkyl group has desirably 1 to 4 carbon atoms, including methylsulfonyl, ethylsulfonyl, propylsulfonyl and isopropylsulfonyl etc.
The alkyl groups which may be fluorinate~ repre-sented by R2, R3 and R4, have desirably 1 to 4 carbon atoms each. Such unsubsti.tuted alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and isobutyl etc.
Such Eluorinated alkyl groups include trifluoromethyl,
2,2,2-trifluoroethyl, 2,2,3,3,3,-pentafluoropropyl, 1-(trifluoromethyl)-2,2,2-tri~luoroethyl, 2,2,3,3-tetra-fluoropropyl and 2,2,3,3,4,4,4-heptafluorobutyl etc.
The alkoxy groups which may be fluorinated, repre-s~nted hy R2, R3 and R4, have ~esirably 1 to 8 carbon atoms each. Such unsubstituted alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, hexyloxy, heptyloxy and octyloxy. Such fluori-nated alkoxy groups include 2,2,2-tri-~luoroethoxy, 2,2,3 t 3,3,-pentafluoropropoxy, 1-(tri1uoromethyl)-2,2,2-tri~luoroethoxy, 2,2,3,3-tetra~luoropropoxy, 2,2,3,3,4,4,4~hepta~1uorobutoxy and 2,2,3,3,4,4,5,5-octa-fluoropentoxy.
In more detail about the compounds ~I) and (II), it is pa~ticul~rl~ desirable that the ring ~ is unsubstituted or substituted at the 4- or 5-position wlth methoxy or trifluoromethyl, R1 ts a hydro~en atom, R2 and R~ are . . : -~ . .
, .

~,6~

1 independen-tly hydrogen atom or methyl and ~3 is a fluorinated alkoxy h~ving 2 to 5 carbol~ atoms.
The vanadium compounds used in this invention include vanadium pentaoxide (V2O5), sodium metavanadate (NaVO3), ammonium metavanadate (NH4V03~ and vanadium (IV) acetyl-acetonate [(CH3COC1l2COCH2)2VO], desirably vanadium penta-oxide, sodium metavanadate and vanadium acetylacetonate.
The amount of -tha vanadium compounds used is generally about 0.01 to 10 mole%, desirably about 0.05 to 2 mole~, particularly desirably about 0.1 to 0.5 mole%
relative to one mole of the compound (I).
Hydrogen peroxide is usually used in an aqueous solution of hydrogen peroxide, but a solution in an orga- `
nic solvent such as n-butylalcohol and a solution in the mi~ture o~ said organic solvent and water may also be used.
The concentration of hydrogen peroxide used in usually lO to 70%, desirably 20 to 40~, but should not be limited only to these ranges.
The amount oE hydrogen peroxide used is usually a slight excess relatlve to olle equivalent of the compound (I), ~0 desirably about 1 to 3 equivalents, more desirably about 1 to 1.5 equivalents.
The solvents used ~or the reaction include haloge-nated hydrocarbons such as chloroform and dichloromethane, ethers such as tetrahydrofuran and dioxane, alcohols such as ethanol, methanol and isopropanol, ketones such as acetone and methyleth~lketone, ~itriles such as aceto-nitrile and water, among which ethanol, methanol, acetone and acetonl-trile are desirable and ethanol is more desir-able. These solven-ts may be used singly or in combi-nation. The amount of the solvent used ~or the reactionis abou-t 0.5 to lO l, desirably about l to 5 l, relative to one mole of the compound (I~, but should no-t be limi-ted only to these ranges.
The re~ction temperature is usually the temperature 35 und~r ice~coollrlg to a~out the boiling point o~ the sol-vent~" usually the temperature under ice~cooling to about 7 ~ 3 3~

1 40C, more desirably about 15 to 30C.
The reaction time is usually about 0.5 to 24 hours, desirably about 1 to 8 hours.
The desired compound (II) produced by tlle reaction described above is usually separated out as crystals from -the reaction mixture, so that the crystals can be collect-ed by filtration after decomposi-tion of the excess of hydrogen peroxide remaining after the reaction by addition of an aqueous solution of sodium thiosulfate, but the crystals may also be collected by extraction with a sol-vent such as chloroform if necessary, followed by concentration~
The crystals thus collec-ted can be purified if neces-sary by a routine method such as recrystallization and chromatography.
The starting compounds (I) can be produced by the methods described in, for example, U.S. Patent No.4255431, European Patent Laid-Open No.45200, No.74341, No.80602, No.5129, No.174726, No.175464 and Great sri-tain Patent Laid-Open No.2l34523A, etc.
According to the method for production of ~s invention, 2-(2-pyridylmethylsulfinyl)benzLmldazole can be cbtained in a good yield (about 85% or more) and with low production of by-products such as 2-(~-pyridylmethylsulfonyl)benzLmidazole N-oxlde~
This invention is illustrated in more detail; in the 2S following Working ~xamples and Refere~ce Example.
Example l 2-[[3-Methyl-4-(2,2,2-tri~luoroethoxy)pyrid-2-yl]-methylthio]benzimidazole (monohydrate) (1.77 g) was dis-solved in dichloromethane (30 ml), to which was added dropwise a-t 15-20C a solut1On of hydrogen peroxide in t-butanol (2.75 ml corresponding to 0.2 g of hydrogen per-oxide~ containing vanadium pentaoxide (5 mg), and then allowed to react at 20-25C ~or about one hour. After completion of the reac-tion,an aqueous solution of sodium thiosulEate (0.5 g/30 ml) was added to the reaction mix-ture, which was stirred vigorously Eor about 10 minutes, allowed to stand still, and separated into layers. 'rhe dichlorolllethane layer was washed with wa~er (30 ml), and concentrated under reduced pressure; to the residue was I

~3~

1 added a mixture of ethanol-water (9:1, 10 ml) Eor crystal~
lization. This solution was ice-cooled, and the crystals were collected by filtration and washed with an ice-cooled mixture o ethanol-water (8 2). The crystals thus ob-tained were treated with a mixture of ethanol-water (9:1, ml), heated (65-70C) and s-tirred for dissolu-tion of the crystals, then the insoluble matters were removed by hot filtration. The filtrate was ice-cooled for crystalliza-tion, and the crystals were collected by filtration, washed with ice-cooled ethanol-water mixture (8:2) and dried in vaccuo to give white crystals of 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]me-thylsulfinyl]benz-imidazole ~1.64 g). (yield: 93.2~).
m.p. 177-178C (decomposed) Example 2 2-[[3-Methyl-~-(2,2,2-trifluoroethoxy)pyrid-2-yl]-metllylthio]benzimidazole (monohydrate) (10.0 g) was dis-solved in ethanol (75 ml)l to which was added a solution of sodium metavanadate (15 mg) in 3~% aqueous solution of hydro~en peroxide(3.07 c3), and allowed to react by stirring at 20-25 for about 8 hours. After completion of the reaction an aqueous solution of sodium thiosulfate (1 g/5 ml) was added to the reaction mixture, which was stirred vigorous-ly for about 10 minutes The crystals were collected by filtration and washed with an ice-cooled mixture of etha-nol-water (1:1). The crystals thus ~btained were -treated with a mixture of ethanol-water (9 1, 50 ml), heated (65-70C) and stirred so -that the crystals were di~solved, then the insoluble ma-tters were removed by ho-t filtra-tlon. The fLltrate was ice cooled Eor crystalliza-tion, and the crystals were collected by Eiltration, washed with ice-cooled ethanol~water mixture (8:2) and dried~ in vaccuo, to cJiVe white needles Gf 2-[[3-methyl-4-(2,2,2-tri~luoroethoxy)pyrld 2-yl]methylsulfinyl]benzimidazole (9.0 CJ). (yield: 90.5'~).
m.p. 177-17a~C (decomposed) c~

_ 9 _ 1 Example 3 2-[[3-Methyl-4-(2,2,2-trifluoroethoxy)pyrid-2-yl]-methylthiojbenzimi~azole (monohydrate) (20.0 g) was dis-solved in ethanol (150 ml), to which was added dropwise at about 20C a solution of vanadium pentaoxide (30 mg) in a mixture of 35~; a~lueous solution of hydrogen peroxide (6 .14 g) and ethanol (6 ml), and allowed to react at 18-22 for about 2.5 hours. After completion of the reaction an aqueous solution of sodium thiosulfate (2 g/60 ml) was added to -the reaction mixture, which was stirred by ice-cooling for about 1 hour. The crystals were collected by filtration .
and washed with an ice-cooled mixture of ethanol-water ~1:1). The crystals thus obtained were treated with a mixture of ethanol-water (9:1, 100 ml), heated (7o-8ooc)and stirred so that the crystals were dissolved, then the insoluble ma-tters were removed by hot fil-tration. The filtrate was lce-cooled for crystallization, and the crystals were collected by filtra-tion, washed with ice-cooled ethanol-water mixture (8:2) and dried in vaccuo, to give white needles of 2-[[3-methyl-4-(2,2,2 trifluoro-ethoxy)pyrid-2-yl]methylsulfinyl]benzimidazole (17.% g).
(yield: 89.5%).
m.p. 177-178C (decomposed) Example 4 Vanadium(IV) acetylacetonate (40 mg) was dissolved in ethanol (150 ml), to which 2-[[3-methyl-4-(2,2,2-tri-fluoroethoxy)pyr.td-2-ylimethylthio]benzimidazole (monohydrate) (20.0 g) was added and then 35~ aqueous solution of hydrogen peroxide (5.14 g) was added dropwise at Z0-25C, and the mixture was allowed to react at 20-25C ~or about 5 hours. After completion of the reaction, a solution o sodium thlosulfate (2.7 g/16 ml) was added to the reaction rnixture and sti.rred vigorously for about 10 minutes- The crystals were collected by filtration and washed wlth an ice-coo:led m:lxture o eth~nol-w~ter (8:2). The crystals thus obt~irled we.re treated w:lth a mixture of ethanol-water
3~

-- 10 ~
.
l (9-1, 90 ml), heated (60-70C) and stirred so th~t the crys-tals were disso]ved, then the insoluble matters were removed by hot filtr~tion. The filtrate was ice-cooled for crystallization and the crystals were collected by filtxation, washed with ice-cooled ethanol-water mixture (8:2) and dried in vaccuo, to give white needles of 2-~[3-methyl-4-(2~2r2-trifluoroethoxy)pyridr2-yl]methylsul-finyl]benzimidazole (18.1 g). (yield: 91.0%).
m.p. 177-178C (decomposed) Example 5 Each 2-[[3-methyl-4-(2t2~2-trifluoroethoxy)pyrid-2 yl]methylsulfinyl~benzimidazole obtained in Exam-ples 1-4 and in Reference Example described below was analyzed by high performance liquid chromatography (HPLC) and the following results were obtained.
Conditions of I~PLC
Equipment used:Shimadzu*~igh Performance Liquid Chromato-graph Type LC-6A
Detector: Shimadzu Ultraviolet Absorption Photometer Type SPD-6A, measurement wave length: 254 nm Data processor: ShimadzuType CR-3A
Column: Nucleosil 5C18 (150 x 40 mm i.d.) Column temperature: a fixed tempera-ture of about 25C
Mobile phase: A mixture of methanol-water-triethylamine (60~40:1) of which pH has been adjusted to 7.0 by addition of phosphoric acid.
Flow rate: 0.7 ml /Inin .
Time required for analysis: 30 minutes Compound Area percentage (%) in high performance liquid chromatography Exam- Exam- Exam- Exam- ReEerence _ _ ple 1 ple 2 ple 3 ple 4 Example sulfoxide derivative 1) 99 3 99.6 ~9.699.7 sa. 9 ~5 N-oxide derivative 2) 0.1 <0 1 <0.l~0,1 O.fi **rrrR(lemark --; ~
.....
::

*1 ) C OC112c~3 ~ J ~ CII.

*2) OCII 2 Cl~ 3 ~N~ Cll~Y~3 1, ~ .
Example 6 According -to the same method as in Example 4, the following compounds were produced and analyzed by HPLC
under the same conditions as in Example 5; the results are summarized as follows.

I~N,~L 11 Cll 2 ~ R ~
o R' , q~

-- 12 ~

-r~ V V V V V

~^
~ u~
~ X ~
~ ~ .

O ~ V~
:~ V V V ~ V V C~ n . ~t~ n ~ ~ _ _ _ t-- ~n co In ~co ~q_ _ .

n n n 1 n ~
r~ ~~ n n n ~ ~
cc ~ ~ cO~ o O

N n n n n _ n n ~ 0 ~0 ~ ~ n n ~a ' " '' , . ' ' . ' .~. ~ ' ~. ; -~2~

~, ~N~ C112~ N~LII ;
I I O 11' U

10 3i~ )dccompos i ~ ion Re~erenGe Example 2-[[3-Methyl-4-t2,2,2-trifluoroethoxy)pyrid-2-yl]methylth.to]benzimida.zole (monohydrate) (20 g) was dissolved in chloroform (200 ml), to which was added slowly dropwise below S C a solution of m-chloroper-benzoic acid (13.5 g) in chloroform (200 ml), and stirred at the same temperature for about 10 minutes. A~ter completion of -the reaction,the reaction mixture was washed wi-th a solution o~ sodium hydrogencarbonate, and dried : over magnesium sulfate, and chloroform was evaporated oE
under reduced pressure. To tha residue was added ethanol (100 ml) ~or crystallization; which was ice-cooled: the resulting crystals were collect~d by filtration and washed with ice-cooled ethanol. The crystals thus obtained were treated with a mixture of ethanol-water (9:1, 90 ml), ~0 heated (65-70C).and stirred SQ that the crys-taIs were dissolved, then the insoluble ma-tters were removed by hot Eiltration. The filtrate was ice-cooled ~or crystal-lization and the crystals we.re collected by filtration, washed wlth ice-cooled ethanol-water mixture (~:2), and dried in vaccuo, to glve white needles o~ 2-[~3-methyl-4-~2,2,2-trl~luoroethoxy)pyrld-2-yl]methylsulEinyl3benz-1 imidazole (14.9 g, yield: 74.9%).
m.p. 177-178C (decomposed) ' .

-~;

'' . ' ' ~ ~ .

Claims (13)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method for producing a compound having the formula:
(II) (wherein the ring A may be substituted; R1 is a hydrogen atom or an N-protective group; R2, R3 and R4 are independently hydrogen atom, an alkyl group which may be fluorinated or an alkoxy group which may be fluorinated), which comprises subjecting a compound having the formula (I) (wherein A, R1, R2, R3 and R4 are the same as described above), to oxidation with hydrogen peroxide in the presence of a vanadium compound.
2. A method according to claim 1, wherein the sub-stituent of the ring A is C1-7 alkyl, halogen, cyano, carboxy, carbo-C1-4 alkoxy, carbo-C1-4 alkoxy-C1-4 alkyl, carbamoyl, carbamoyl-C1-4 alkyl, hydroxy, C1-5 alkoxy, hydroxy-C1-7 alkyl, trifluoromethyl, C1-4 acyl, carbamoyl-oxy, nitro, C1-4 acyl-oxy, aryl, aryloxy, C1-4 alkyl-thio or C1-6 alkyl-sulfinyl.
3. A method according to claim 1, whe.rein the N-protective group is C1-5 alkyl, C1-4 acyl, carbo-C1-4 alkoxy, carbomoyl, C1-4 al]cyl-carbamoyl, di(C-4 alkyl)-carbamoyl, C1-4 alkyl-carbonylmethyl, C1-4 alkoxy-carbonylmethyl or C1-4 alkyl-sulfonyl.
4. A method according to claim 1, wherein R2, R3 and R4 are independently C1-4 alkyl which may be fluorinated or C1-8 alkoxy which may be fluorinated.
5. A method according to claim 1, wherein the ring A is unsubstituted or substituted at the 4- or 5-position with methoxy or trifluoromethyl, R1 is hydrogen, R2 and R4 are independently hydrogen or methyl and R3 is a fluorinated C2-5 alkoxy.
6. A method according to claim 1, wherein the vanadium compound is vanadium pentaoxide, sodium metavanadate, ammonium metavanadate or vanadium (IV) acetylacetonate.
7. A method according to claim 1, wherein the vanadium compound is used in an amount of about 0.01 to 10 mole %
relative to the compound having the formula:

(I)
8. A method according to claim 1, wherein hydrogen peroxide is used in an amount of about 1 to 3 equivalents relative to the compound having the formula:

(I)
9. A method according to claim 2 or 3, wherein R2, R3 and R4 are independently C1-4 alkyl which may be fluorinated or C1-8 alkoxy which may be fluorinated.
10. A method according to claim 2, 3 or 4, wherein the ring A is unsubstituted or substituted at the 4- or 5-position with methoxy or trifluoromethyl, R1 is hydrogen, R2 and R4 are in-dependently hydrogen or methyl and R3 is a fluorinated C2-5 alkoxy.
11. A method according to claim 5, 7 or 8, wherein the vanadium compound is vanadium pentaoxide, sodium metavanadate, ammonium metavanadate or vanadium (IV) acetylacetonate.
12. A method according to claim 2, 3 or 5, wherein the vanadium compound is vanadium pentaoxide, sodium metavanadate, ammonium metavanadate or vanadium (IV) acetylacetonate; the vanadium compound is used in an amount of about 0.01 to 10 mole %
relative to the compound of the formula (I); and hydrogen peroxide is used in an amount of about 1 to 3 equivalents relative to the compound of the formula (I).
13. A method according to claim 2, 3 or 5, wherein the vanadium compound is vanadium pentaoxide, sodium metavanadate, ammonium metavanadate or vanadium (IV) acetylacetonate; the vanadium compound is used in an amount of about 0.05 to 2 mole %
relative to the compound of the formula (I); hydrogen peroxide is used in an amount of about 1 to 3 equivalents relative to the com-pound of the formula (I) using a solvent selected from the class consisting of halogenated hydrocarbon solvents, ether solvents, alcohol solvents, ketone solvents, nitrile solvents, water and mixtures thereof; and the oxidation reaction is carried out at an ice-cooling temperature to about 40°C.
CA000573673A 1987-08-04 1988-08-03 Production of 2-(2- pyridylmethylsulfinyl)benzimidazole compounds Expired CA1263119A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP194809/1987 1987-08-04
JP19480987 1987-08-04

Publications (1)

Publication Number Publication Date
CA1263119A true CA1263119A (en) 1989-11-21

Family

ID=16330618

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000573673A Expired CA1263119A (en) 1987-08-04 1988-08-03 Production of 2-(2- pyridylmethylsulfinyl)benzimidazole compounds

Country Status (11)

Country Link
US (1) US5578732A (en)
EP (1) EP0302720B1 (en)
KR (1) KR960000047B1 (en)
AT (1) ATE82283T1 (en)
CA (1) CA1263119A (en)
DE (1) DE3875848T2 (en)
DK (1) DK171989B1 (en)
ES (1) ES2052728T3 (en)
GR (1) GR3006974T3 (en)
HU (1) HU199828B (en)
IE (1) IE61717B1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012590A1 (en) 1993-11-04 1995-05-11 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole and intermediates useful therein
US6077541A (en) * 1997-11-14 2000-06-20 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6121454A (en) * 1997-05-06 2000-09-19 Pdi-Research Laboratories, Inc. Synthesis of pharmaceutically useful pyridine derivatives
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6437139B1 (en) 1997-05-06 2002-08-20 Pdi-Research Laboratories, Inc. Synthesis of pharmaceutically useful pyridine derivatives
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US7129358B2 (en) 2001-02-02 2006-10-31 Teva Pharmaceutical Industries Ltd. Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
WO2013108068A1 (en) 2012-01-21 2013-07-25 Jubilant Life Sciences Limited Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK171989B1 (en) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Process for the preparation of 2- (2-pyridylmethylsulfinyl) benzimidazoles
SE8804629D0 (en) * 1988-12-22 1988-12-22 Ab Haessle NEW THERAPEUTICALLY ACTIVE COMPOUNDS
CA2053527C (en) 1990-10-17 2002-03-12 Takashi Sohda Pyridine derivatives, their production and use
ES2026761A6 (en) * 1990-10-31 1992-05-01 Genesis Para La Investigacion A process for the preparation of omeprazol.
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
BR9306702A (en) * 1992-07-08 1998-12-08 Monsanto Co Benzimidazoles to relieve stomach ulcers in pigs
ES2060541B1 (en) * 1993-02-26 1995-11-16 Vinas Lab NEW PROCEDURE FOR THE SYNTHESIS OF A DERIVATIVE OF 2- (2-PIRIDILMETILSUFINIL) BENCIMIDAZOLE, AND NEW INTERMEDIATE PRODUCTS OBTAINED WITH THE SAME.
ES2063705B1 (en) * 1993-06-14 1995-07-16 S A L V A T Lab Sa INTERMEDIATE FOR THE SYNTHESIS OF LANSOPRAZOLE AND ITS PROCEDURE FOR OBTAINING.
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
KR100458170B1 (en) * 1997-05-26 2005-05-03 동아제약주식회사 New preparation method of 2- [3-methoxy-4- (2,2,2-trifluoroethoxy) 2-pyridyl] methylsulfinyl-1H-benzimidazole
US6303787B1 (en) * 1998-05-27 2001-10-16 Natco Pharma Limited Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates
US6166213A (en) * 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof
US6191148B1 (en) 1998-08-11 2001-02-20 Merck & Co., Inc. Omerazole process and compositions thereof
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
PL333847A1 (en) * 1999-06-18 2001-01-02 Inst Farmaceutyczny Crystalline forms of lansoprozole and method of obtaining lansoprazole in pharmacologically advanthageous crystalline form
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
AU5705700A (en) 1999-06-30 2001-01-22 Takeda Chemical Industries Ltd. Crystals of benzimidazole compounds
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
KR100362947B1 (en) * 1999-09-21 2002-11-30 주식회사 대웅 Process for Preparing Sulfoxide Compound
DE19951960C2 (en) * 1999-10-28 2002-06-27 Gruenenthal Gmbh Process for the preparation of benzimidazole derivatives suitable as ulcer therapeutics
EP1293507B1 (en) * 2000-05-15 2007-11-28 Takeda Pharmaceutical Company Limited Process for producing crystal
KR20100002278A (en) 2000-12-01 2010-01-06 다케다 야쿠힌 고교 가부시키가이샤 Crystal of (r)- or (s)-lansoprazole
KR100430575B1 (en) * 2001-02-21 2004-05-10 주식회사 씨트리 Method of Preparing Lansoprazole and Its Intermediate
KR100783020B1 (en) * 2001-03-23 2007-12-07 동아제약주식회사 2-Methylchloride Pyridine Derivative and Preparation Method of Benzimidazole Derivative Using the Same
US20040248941A1 (en) * 2001-09-25 2004-12-09 Keiji Kamiyama Benzimidazone compound, process for producing the same, and use thereof
AU2003224779A1 (en) * 2002-03-27 2003-10-13 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
KR100873419B1 (en) * 2002-06-18 2008-12-11 페어차일드코리아반도체 주식회사 Power semiconductor devices with high breakdown voltage, low on-resistance and small switching losses
EP1467987A1 (en) * 2002-07-26 2004-10-20 Teva Pharmaceutical Industries Ltd. Preparation of lansoprazole and related compounds
ATE375338T1 (en) * 2002-08-21 2007-10-15 Teva Pharma METHOD FOR THE PURIFICATION OF LANZOPRAZOLE
EP1764364A1 (en) * 2002-08-21 2007-03-21 Teva Pharmaceutical Industries Ltd A method for the purification of lansoprazole
EP1552833B1 (en) * 2002-10-16 2016-12-28 Takeda Pharmaceutical Company Limited Process for producing an amorphous optically active isomer of lansoprazole
EP1465890B1 (en) * 2002-11-18 2007-04-04 Teva Pharmaceutical Industries Ltd. Stable lansoprazole containing more than 500 ppm, up to about 3,000 ppm water and more than 200 ppm, up to about 5,000 ppm alcohol
US7507829B2 (en) 2002-12-19 2009-03-24 Teva Pharmaceuticals Industries, Ltd Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
US7678816B2 (en) * 2003-02-05 2010-03-16 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
EP1608649A2 (en) * 2003-03-28 2005-12-28 Sidem Pharma SA Method for the enantioselective preparation of sulphoxide derivatives
FR2852956B1 (en) * 2003-03-28 2006-08-04 Negma Gild PROCESS FOR THE ENANTIOSELECTIVE PREPARATION OF SULFOXIDE DERIVATIVES
MXPA05013316A (en) 2003-06-10 2006-03-17 Teva Pharma Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole.
EP1768668A2 (en) 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
EP1790647B1 (en) 2004-09-13 2013-05-08 Takeda Pharmaceutical Company Limited Method for producing oxidized compound
EP1681056A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
KR100758600B1 (en) * 2006-01-05 2007-09-13 주식회사 대웅제약 Method for preparing lansoprazole crystalline form A
WO2008035189A1 (en) * 2006-09-22 2008-03-27 Orchid Chemicals & Pharmaceuticals Limited A method for the purification of lansoprazole
WO2008092939A2 (en) 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
WO2009066309A2 (en) * 2007-07-12 2009-05-28 Cadila Healthcare Limited Process for preparation of omeprazole
CN102014638A (en) 2007-10-12 2011-04-13 武田制药北美公司 Method of treating gastrointestinal disorders independent of food intake
AU2009224247B2 (en) 2008-03-10 2013-12-12 Takeda Pharmaceutical Company Limited Crystal of benzimidazole compound
ES2343935B1 (en) * 2008-12-29 2011-04-28 Laboratorios Viñas S.A. USEFUL INTERMEDIATES FOR OBTAINING 2- (2-PIRIDINILMETILSULFINIL) -1H-BENZIMIDAZOLES AND CORRESPONDING PROCEDURES.
KR20100101405A (en) * 2009-03-09 2010-09-17 한미홀딩스 주식회사 Method of preparing non-crystalline (+)-lansoprazole and (+)-lansoprazole alcoholate used therein
CN102180865B (en) * 2011-03-17 2013-01-16 浙江工业大学 Synthesis method of lansoprazole
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103724325B (en) * 2013-12-10 2016-04-13 南京工业大学 Process for preparing sulfinyl-1-hydro-benzimidazole derivatives
CN104019635B (en) * 2014-06-19 2015-05-27 上海慈瑞医药科技有限公司 Drying process for lansoprazole bulk drug
CN116891458A (en) * 2023-06-19 2023-10-17 南京唯创远医药科技有限公司 A kind of preparation method of ilaprazole

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (en) * 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
HU195220B (en) * 1983-05-03 1988-04-28 Byk Gulden Lomberg Chem Fqb Process for production of new fluor-alkoxi-benzimidasole-derivatives and medical compositions containig them
JPS6150979A (en) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd Pyridine derivative and preparation thereof
JPS6150978A (en) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd Pyridine derivative and preparation thereof
US4738975A (en) * 1985-07-02 1988-04-19 Takeda Chemical Industries, Ltd. Pyridine derivatives, and use as anti-ulcer agents
DK171989B1 (en) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Process for the preparation of 2- (2-pyridylmethylsulfinyl) benzimidazoles

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012590A1 (en) 1993-11-04 1995-05-11 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole and intermediates useful therein
US6121454A (en) * 1997-05-06 2000-09-19 Pdi-Research Laboratories, Inc. Synthesis of pharmaceutically useful pyridine derivatives
US6437139B1 (en) 1997-05-06 2002-08-20 Pdi-Research Laboratories, Inc. Synthesis of pharmaceutically useful pyridine derivatives
US6077541A (en) * 1997-11-14 2000-06-20 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6780435B2 (en) 1997-11-14 2004-08-24 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6855336B2 (en) 1998-08-28 2005-02-15 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US7129358B2 (en) 2001-02-02 2006-10-31 Teva Pharmaceutical Industries Ltd. Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles
EP1970374A1 (en) 2001-02-02 2008-09-17 Teva Pharmaceutical Industries Ltd. Process for the production of substituted 2-(pyridin-2-ylmethylsulfinyl)-1H-benzimidazoles
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
WO2013108068A1 (en) 2012-01-21 2013-07-25 Jubilant Life Sciences Limited Process for the preparation of 2-pyridinylmethylsulfinyl benzimidazoles, their analogs and optically active enantiomers

Also Published As

Publication number Publication date
EP0302720A1 (en) 1989-02-08
DK428188D0 (en) 1988-08-01
IE882376L (en) 1989-02-04
US5578732A (en) 1996-11-26
HU199828B (en) 1990-03-28
DE3875848D1 (en) 1992-12-17
ES2052728T3 (en) 1994-07-16
KR890003738A (en) 1989-04-17
GR3006974T3 (en) 1993-06-30
EP0302720B1 (en) 1992-11-11
ATE82283T1 (en) 1992-11-15
DK428188A (en) 1989-02-05
KR960000047B1 (en) 1996-01-03
DE3875848T2 (en) 1993-03-25
DK171989B1 (en) 1997-09-08
HUT49346A (en) 1989-09-28
IE61717B1 (en) 1994-11-30

Similar Documents

Publication Publication Date Title
US5578732A (en) Production of 2-(2-pyridylmethylsulfinyl) benzimidazole compounds by selective oxidation in the presence of a vanadium catalyst
KR101035534B1 (en) Method of Making Crystal
KR100242622B1 (en) Proces for the preparation of anti-ulcer agents
US6545024B1 (en) Sulfoxide compounds and acetone complexes, and a process for producing the same
RU2345075C2 (en) Method of obtaining pharmaceutical remedies and compounds obtained by claimed method
CA2402635C (en) Method for oxidizing a thioether group into a sulfoxide group
WO1982002042A1 (en) Azetidine derivatives and process for their preparation
MC1970A1 (en) ACYL DERIVATIVES
WO2008004245A1 (en) Process for the preparation of optically pure or optically enriched enantiomers of sulphoxide compounds
RU2237671C1 (en) Method and ester derivatives used for preparing cephalosporins
CA1275405C (en) Penem derivatives
KR101370844B1 (en) Process for the preparation of pantoprazole sodium
EP1476441B1 (en) A method of eliminating sulfone analog in the synthesis of pyridine-benzimidazole sulfoxides
EP0298177A1 (en) Process for preparing pristinamycine IIB derivatives
SU858565A3 (en) Method of preparing 1,3-perhydrothiazine derivatives
JPH0686444B2 (en) Process for producing 2- (2-pyridylmethylsulfinyl) benzimidazole compound
KR100869677B1 (en) Method of Making Crystal
KR960011778B1 (en) Novel process for preparing crystalline hydrate of cephalosporin
KR100464174B1 (en) A process for preparation of sulfinyl benzimidazole derivatives
HU195222B (en) Process for production of pename-, cefem- and cefamsulphons
CZ286105B6 (en) Process for preparing 2-azetidinones and intermediate for preparation thereof
KR20020068140A (en) Method for Preparing [(2-Oxo-3-tetrahydrothienylcarbamoyl)-methyl thio] acetic acid
BE821163A (en) PENAM DERIVATIVES AND THEIR PREPARATION
HK40011933A (en) Method for preparing intermediate of 4-methoxypyrrole derivative
EP0120094A1 (en) Azetidinone compounds

Legal Events

Date Code Title Description
MKEX Expiry